SCHEMBL1377274

SCHEMBL1377274

NC(=O)C(CCC(=O)O)C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.54
GRM8 O00222 1/20 0.54
GRM6 O15303 1/20 0.54
GRIN2D O15399 1/20 0.54
GRIN3B O60391 1/20 0.54
GSR P00390 1/20 0.54
GRIK1 P39086 1/20 0.54
GRM5 P41594 1/20 0.54
GRIA1 P42261 1/20 0.54
GRIA2 P42262 1/20 0.54
GRIA3 P42263 1/20 0.54
SLC1A3 P43003 1/20 0.54
SLC1A2 P43004 1/20 0.54
SLC1A1 P43005 1/20 0.54
GRIA4 P48058 1/20 0.54
GRIN1 Q05586 1/20 0.54
GRIN2A Q12879 1/20 0.54
GRIK2 Q13002 1/20 0.54
GRIK3 Q13003 1/20 0.54
GRIN2B Q13224 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27537439 0.84 KMT2A (0.58) CYP1A2GRM8GRM6GRIN2DGRIN3B
SCHEMBL669817 0.83 FOLH1 (0.64) CYP1A2GRM8GRM6GRIN2DGRIN3B
SCHEMBL29624210 0.81 LMNA (0.52) TSHRLMNAPMP22ENPEPCYP2D6
SCHEMBL6894682 0.80 CYP1A2 (0.56) CYP1A2GRM8GRM6GRIN2DGRIN3B
SCHEMBL27473595 0.78 FOLH1 (0.58) CYP1A2GRM8GRM6GRIN2DGRIN3B
SCHEMBL31612214 0.77 PMP22 (0.50) CYP1A2GRM8GRM6GRIN2DGRIN3B
SCHEMBL18342682 0.76 GABRR1 (0.50) CYP1A2GRM8GRM6GRIN2DGRIN3B
SCHEMBL7624643 0.74 CHRM1 (0.52) GRIK1SLC1A3SLC1A2SLC1A1GRIK2
SCHEMBL965272 0.74 GRM8 (0.68) CYP1A2GRM8GRM6GRIN2DGRIN3B
SCHEMBL509039 0.74 FOLH1 (0.54) CYP1A2GRM8GRM6GRIN2DGRIN3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12496292-B2 PSMA binding ligand-linker conjugates and methods for using PURDUE RESEARCH FOUNDATION (US) 2025-12-16 US disclosed
US-20250108039-A1 PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING PURDUE RESEARCH FOUNDATION 2025-04-03 US disclosed
EP-4464384-A2 PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING Purdue Research Foundation (US) 2024-11-20 EP disclosed
US-12091693-B2 PSMA binding ligand-linker conjugates and methods for using PURDUE RESEARCH FOUNDATION (US) 2024-09-17 US disclosed
US-20230346752-A1 PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING PURDUE RESEARCH FOUNDATION 2023-11-02 US disclosed
US-20230293497-A1 PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING PURDUE RESEARCH FOUNDATION (US) 2023-09-21 US disclosed
US-11717514-B2 PSMA binding ligand-linker conjugates and methods for using PURDUE RESEARCH FOUNDATION (US) 2023-08-08 US disclosed
US-20230000836-A1 PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING PURDUE RESEARCH FOUNDATION 2023-01-05 US disclosed
US-11504357-B2 PSMA binding ligand-linker conjugates and methods for using PURDUE RESEARCH FOUNDATION (US) 2022-11-22 US disclosed
US-11369590-B2 PSMA binding ligand-linker conjugates and methods for using PURDUE RESEARCH FOUNDATION (US) 2022-06-28 US disclosed
WO-2014085575-A1 METHODS FOR TREATING CANCER USING COMBINATION THERAPIES ENDOCYTE, INC. (US) 2014-06-05 WO disclosed
US-20140073763-A1 PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING PURDUE RESEARCH FOUNDATION (US) 2014-03-13 US disclosed
US-20120322741-A1 PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING PURDUE RESEARCH FOUNDATION (US) 2012-12-20 US disclosed
US-20110288152-A1 PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING PURDUE RESEARCH FOUNDATION (US) 2011-11-24 US disclosed
WO-2011106639-A1 PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING PURDUE RESEARCH FOUNDATION (US) 2011-09-01 WO disclosed
CN-102014956-A PSMA binding ligand-linker conjugates and methods of use thereof PURDUE RESEARCH FOUNDATION 2011-04-13 CN disclosed
US-20100324008-A1 PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING PURDUE RESEARCH FOUNDATION (US) 2010-12-23 US disclosed
EP-2187965-A1 PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING PURDUE RESEARCH FOUNDATION (US) 2010-05-26 EP disclosed
WO-2010045598-A2 PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING PURDUE RESEARCH FOUNDATION (US) 2010-04-22 WO disclosed
WO-2009026177-A1 PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING PURDUE RESEARCH FOUNDATION (US) 2009-02-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230293497-A1 PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING FOLH1, KLK3, PSMA1 CYP1A2 4799/4885GRM8 469/4885GRM6 932/4885
US-20110288152-A1 PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING FOLH1, KLK3, PSMA1 CYP1A2 4850/4885GRM8 569/4885GRM6 991/4885
US-20250108039-A1 PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING FOLH1, KLK3, PSMA1 CYP1A2 4799/4885GRM8 469/4885GRM6 932/4885
US-12496292-B2 PSMA binding ligand-linker conjugates and methods for using FOLH1, KLK3, PSMA1 CYP1A2 4799/4885GRM8 469/4885GRM6 932/4885
US-11369590-B2 PSMA binding ligand-linker conjugates and methods for using FOLH1, KLK3, PSMA1 CYP1A2 4799/4885GRM8 469/4885GRM6 932/4885
US-12091693-B2 PSMA binding ligand-linker conjugates and methods for using FOLH1, KLK3, PSMA1 CYP1A2 4797/4885GRM8 473/4885GRM6 904/4885
US-20120322741-A1 PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING FOLH1, KLK3, PSMA1 CYP1A2 4797/4885GRM8 473/4885GRM6 904/4885
US-20230000836-A1 PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING FOLH1, KLK3, PSMA1 CYP1A2 4799/4885GRM8 469/4885GRM6 932/4885
US-20100324008-A1 PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING FOLH1, KLK3, PSMA1 CYP1A2 4799/4885GRM8 469/4885GRM6 932/4885
US-20140073763-A1 PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING FOLH1, KLK3, PSMA1 CYP1A2 4799/4885GRM8 469/4885GRM6 932/4885
US-11504357-B2 PSMA binding ligand-linker conjugates and methods for using FOLH1, KLK3, PSMA1 CYP1A2 4799/4885GRM8 469/4885GRM6 932/4885
US-11717514-B2 PSMA binding ligand-linker conjugates and methods for using FOLH1, KLK3, PSMA1 CYP1A2 4799/4885GRM8 469/4885GRM6 932/4885
US-20230346752-A1 PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING FOLH1, KLK3, PSMA1 CYP1A2 4799/4885GRM8 469/4885GRM6 932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.